RPRX 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-05

• For the Three Months Ended June 30,For the Six Months Ended June 30,

• Other royalty income and revenues primarily includes income from financial royalty assets that have been fully amortized, on which we may continue to collect royalties beyond the estimated duration, and income from synthetic royalties and milestones arising out of R&D funding agreements.

• We enter into R&D funding agreements with counterparties to acquire royalties or milestones on product candidates. R&D funding expense consists of development-stage funding costs recognized under these agreements, which may be made upfront, as milestones upon achievement of certain predefined criter…

• For the Three Months Ended June 30,ChangeFor the Six Months Ended June 30,Change

• Income from financial royalty assets by top products is as follows, in order of contribution to income for the first six months of 2026 (in thousands):

相对上期删除的文字 · 来源:10-Q · 2026-05-06

• Other royalty income and revenues primarily includes income from financial royalty assets that have been fully amortized and income from synthetic royalties and milestones arising out of R&D funding arrangements. Occasionally, a royalty asset may be amortized on an accelerated basis due to collectab…

• R&D funding expense consists of certain development-stage funding payments that we have made to counterparties to acquire royalties or milestones on product candidates. The payments can be made on an upfront basis, upon pre-approval milestones or over time as the related product candidates undergo c…

• Provision for changes in expected cash flows from financial royalty assets(197,485)(127,140)(70,345)55.3

• Provision for credit losses on unfunded commitments(3,700)— (3,700)n/a

• Income from financial royalty assets by top products is as follows, in order of contribution to income for the first quarter of 2026 (in thousands):

相对上期新增的文字 · 来源:10-Q · 2026-08-05

• (2)On June 26, 2026, Dr. Urist entered into a Trading Plan, scheduled to commence on September 28, 2026 and end on October 9, 2026, providing for the sale of up to 100% of the Class A ordinary shares that may be issued upon settlement of EPAs in August 2026.

相对上期删除的文字 · 来源:10-Q · 2026-05-06

• (2)Maximum shares subject to trading plan consists of up to 214,091 Class A ordinary shares and 100% of the shares that may be issued upon settlement of the EPAs awarded for the first and second quarters of 2026.

• (3)On February 12, 2026, Dr. Urist entered into a Trading Plan, scheduled to commence on May 14, 2026 and end on May 26, 2026, providing for the sale of up to 27,368 Class A ordinary shares. In addition, on March 25, 2026, Dr. Urist entered into a Trading Plan, scheduled to commence on June 24, 2026…